YOUJIA BIO
Nucleic Acid Drug Developer
May 27, 2024
eMedClub News
May
Recently,Youjia (Hangzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as: YOUJIA BIO) and Sichuan Luzhou Bubu Biopharmaceutical Co., Ltd. (hereinafter referred to as: Bubu Biopharmaceutical) officially signed the "Development Contract for Innovative siRNA Therapeutics Targeting Cardiovascular Indications" in Beijing, and byYOUJIA BIO Grants Sichuan Luzhou Bubu Biopharmaceutical Co., Ltd. Exclusive Licensing Cooperation Rights to Jointly Advance Clinical Translation of Innovative Drugs and Open a New Chapter in Cardiovascular Disease Prevention and Treatment.
Precision Targeting, Technical Excellence: Laying the Foundation for Multiple "Heart" Benefits
Cardiovascular diseases have always been the leading cause of death globally and a severe public health issue. According to the "Report on Cardiovascular Health and Diseases in China 2022," cardiovascular diseases top the list of causes of death among Chinese residents, with an estimated 330 million patients in China, and the incidence rate is still on a continuous rise.
In recent years, the influx of a large number of innovative drugs has provided a broad perspective for etiological research in the cardiovascular field, the establishment of new concepts, and the formulation of new diagnostic and treatment methods. Among them, siRNA drugs, as an innovative therapeutic solution that uses precise gene regulation as a handle, can achieve precise degradation of specific mRNA and block protein synthesis without affecting the original DNA sequence or other gene expressions, bringing multiple benefits such as high efficacy, long duration, safety, and convenience:
l Potent: Optimization and selection of siRNA sequences lead to more precise and potent target gene silencing effects;
Long-acting: An upstream mechanism of action can achieve ultra-long efficacy, while advancements in the delivery system ensure that siRNA is protected from clearance and effectively transported to the target.
l Safety: The designed and chemically modified siRNA sequences can reduce their off-target toxicity or other toxic effects;
l Convenience: Ultra-long dosing intervals revolutionize traditional chronic disease management models, enhancing patient compliance;
Mature target selection and gene sequence design, excellent chemical modification technology, and delivery systems are key links to achieving the clinical transformation of siRNA. They are also one of the R&D challenges faced by many pharmaceutical companies in China. YOUJIA BIO, as a representative enterprise in the development of siRNA drugs in China, has a complete nucleic acid drug development platform. It has built an intelligent NDDS system for target selection and sequence design, a third-generation chemical modification CMS3 technology, and a diversified delivery system with independent intellectual property rights that meets various administration methods and targeting needs—CPNP, PNAC, and LNP—to improve the clinical transformation of siRNA drugs and make long-term preparations for challenging the development of optimal siRNA.
Promote Cooperation, Share and Win Together, and Boost the Takeoff of China-Produced Innovative Drugs
At the signing ceremony, Dr. Yang Chun, Chairman of Sichuan Luzhou Bubu Biopharmaceutical Co., Ltd., stated that YOUJIA BIO, as a representative company in China's nucleic acid drug research and development, has demonstrated its technical strength and innovative achievements in the industry. For instance, the company’s self-developed anti-liver fibrosis siRNA drug has successfully applied to the U.S. FDA for an Investigational New Drug (IND) application, fully demonstrating its outstanding R&D capabilities in the siRNA field. It is believed that through this collaboration, both parties will optimize clinical research management models and advance and lead a new era of chronic cardiovascular disease treatment with siRNA drugs as the primary strategy.
June 14-15
IBI EXPO
Recommended Thematic Forums
Scan the code
Limited Time Offer
Free Tickets
AboutBubu Bio
About YOUJIA BIO
Youjia (Hangzhou) Biomedical Technology Co., Ltd. ("YOUJIA BIO") was jointly founded by several overseas returnee doctors and a team with rich industrialization experience. Located in the Yangtze River Delta International Biomedical Industry Park, Xiaoshan Economic and Technological Development Zone, Hangzhou City, Zhejiang Province, the company owns molecular biology and chemical laboratories covering nearly 1,500 square meters. With the starting point of meeting clinical needs, it takes the mission of developing affordable innovative drugs for the general public. Its product pipeline has covered areas such as antiviral, anti-fibrosis, and cardiovascular diseases. Currently, a mature full-process development platform for nucleic acid drugs has been established, including the NDDS system for intelligent design of nucleic acid drugs, drug evaluation system, delivery system, and CMC platform for nucleic acid drugs.
Statement:This article aims to convey industry development information and explore the frontier progress of biomedicine.The content of the article represents the author's viewpoint and does not represent the position of EBCmed, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a regular hospital for medical advice.
DianDian "Share”、“Like" and "In view", charge me up a bit~"